The Use of IO Doublet in PD-L1-Negative NSCLC

David Carbone

2024 Intervention Selection & Sequencing in Early Stage NSCLC

Total Health

J. Porter

Year in Review: Lung Cancer

Balazs Halmos

RheumNow News Highlights: 11 Agents That Cause Arthritis, Lupus - Te…

RheumNow

J. Cush

Clinical Highlights From AACR 2024: Trials Evaluating Selected New T…

AdventHealth

G. Sonpavde

Advances in the Treatment of Melanoma

Masterclasses in Dermatology

D. Fisher

Clinical Approach to Diagnosis and Treatment of Cytokine Storm in Rh…

Cleveland Clinic Rheumatology

R. Q. Cron

ASCO® 2024 Lung Cancer Highlights: Top Abstracts Including BEAT-SC, …

2024 ASCO® Annual Meeting Insights Hub

B. Halmos

ASCO® 2024 Summary: "My Personal Highlights in Melanoma"

2024 ASCO® Annual Meeting Insights Hub

S. Patel

Updates in the Management of NSCLC: Systemic Therapy Year in Review

Total Health

W. Iams

Hyperprogression in Cancer Treated With Immunotherapy

Northwestern Medicine Oncology and Hematology

Y. Chae

FDA Approval of Lifileucel for Unresectable or Metastatic Melanoma: …

Stanford Medicine

A. Betof Warner

Hair Graying and the Melanocyte: Mechanisms and Melanoma Implications

Masterclasses in Dermatology

D. Fisher

Checkpoint Inhibitors and Rheumatic Disease

NYU Langone

A. Bass

Mediastinal Staging of Lung Cancer

MI&T Congressi

R. Trisolini

The NADINA Trial - A Paradigm Shift in Melanoma Treatment

Oncology Data Advisor

M. Hadfield

AAD 2024 Insights: What's New In Nail Tumors

AAD 2024

J. Dominguez-Cherit

The Role of Adjuvant IO vs. Targeted Therapy for BRAF V600-Mutant St…

Tarek Haykal

Recent NSCLC Updates Including PAPILLON, CHECKMATE 77T, and KEYNOTE-…

ecancer

L. Raez

Optimal Treatment for BRAF-Mutated Metastatic Melanoma

Jeff Yorio